Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
20.47
0.00 (0.00%)
At close: Feb 27, 2026, 4:00 PM EST
20.54
+0.07 (0.34%)
After-hours: Feb 27, 2026, 4:10 PM EST
Sutro Biopharma Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Sutro Biopharma stock have an average target of 18.88, with a low estimate of 8.00 and a high estimate of 30. The average target predicts a decrease of -7.77% from the current stock price of 20.47.
Analyst Consensus: Hold
* Price targets were last updated on Jan 20, 2026.
Analyst Ratings
The average analyst rating for Sutro Biopharma stock from 8 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 5 | 5 | 5 | 6 | 5 | 5 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Hold → Buy Upgrades $23 | Hold → Buy | Upgrades | $23 | +12.36% | Jan 20, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $2 → $10 | Hold | Maintains | $2 → $10 | -51.15% | Dec 22, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $40 → $30 | Hold | Maintains | $40 → $30 | +46.56% | Aug 12, 2025 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $20 | Hold → Buy | Upgrades | $20 | -2.30% | Jun 16, 2025 |
| B of A Securities | B of A Securities | Sell Maintains $10 → $8 | Sell | Maintains | $10 → $8 | -60.92% | May 19, 2025 |
Financial Forecast
Revenue This Year
101.18M
from 62.04M
Increased by 63.08%
Revenue Next Year
45.09M
from 101.18M
Decreased by -55.43%
EPS This Year
-22.33
from -29.61
EPS Next Year
-19.08
from -22.33
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 115.5M | 63.0M | ||||
| Avg | 101.2M | 45.1M | ||||
| Low | 89.0M | 9.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 86.2% | -37.7% | ||||
| Avg | 63.1% | -55.4% | ||||
| Low | 43.5% | -90.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -19.74 | -4.46 | ||||
| Avg | -22.33 | -19.08 | ||||
| Low | -26.85 | -71.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.